Keywords: Sanofi, ImmunoGen, SAR3419, Ph II, Aubagio, Multiple sclerosis, NDA, Genzyme

Sanofi pays $3 million milestone to ImmunoGen on start of SAR3419 Ph II testing; FDA accepts Aubagio filing

Article | 21 October 2011

Print This

US biotech firm ImmunoGen (Nasdaq: IMGN) says that SAR3419 has started Phase II testing, which triggers a $3 million milestone payment ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in